Dapagliflozin Ameliorates Diabetic Kidney Disease <i>via</i> Upregulating Crry and Alleviating Complement Over-activation in <i>db/db</i> Mice.

Front Pharmacol · 2021 · PMC8546210 · PMID 34712135

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

marginally significantno p-value reported

Marginally significant decreasing of UACR was observed in dapagliflozin-treated db/db mice compared with vehicle-treated db/db mice (385.53 ± 178.27 mg/g Cr vs. 230.40 ± 72.48 mg/g Cr, p = 0.054).

also in 26,082 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.